https://www.pharmaradar360.com/article/d15d4ea013830c50PharmaRadar360en2026-04-22T11:03:43.000ZCertara Enters Definitive Agreement for the Sale of its Regulatory and Medical Writing Business to Veristathttps://www.pharmaradar360.com/article/338a161945265544PharmaRadar360en2026-04-22T11:00:00.000ZWater, Energy, Circularity: Technologies for a Resilient Futurehttps://www.pharmaradar360.com/article/0e3db441067392afPharmaRadar360en2026-04-22T11:00:00.000ZLabcorp Launches FDA-Approved Companion Diagnostic to Identify Patients with Ovarian Cancer Eligible for KEYTRUDA®https://www.pharmaradar360.com/article/1193490a45dd9de6PharmaRadar360en2026-04-22T10:57:04.000ZFDA approves MSD’s once-daily HIV combo Idvynsohttps://www.pharmaradar360.com/article/2889056a474d95f5PharmaRadar360en2026-04-22T10:46:07.000ZBösartige Weichgewebetumoren besser behandelnhttps://www.pharmaradar360.com/article/1295a48b4a989050PharmaRadar360en2026-04-22T10:30:49.000ZAstraZeneca to seek accelerated approval of Ultomirisin in IgAN on Phase III datahttps://www.pharmaradar360.com/article/b1d0b38151355c23PharmaRadar360en2026-04-22T10:30:00.000ZBoston Scientific announces results for first quarter 2026https://www.pharmaradar360.com/article/8b94769ceda4bf24PharmaRadar360en2026-04-22T10:01:53.000ZESCMID Global 2026: SCY-247 as novel invasive candidiasis therapyhttps://www.pharmaradar360.com/article/69436194b459b13aPharmaRadar360en2026-04-22T10:00:22.000ZClass 4 Medicines Defect Notification: Doncaster Pharma Limited, Hiprex 1g tablets, EL(26)A/20https://www.pharmaradar360.com/article/937a558f0fe20b4ePharmaRadar360en2026-04-22T10:00:20.000ZKing’s College Hospital achieves HIMSS INFRAM stage sixhttps://www.pharmaradar360.com/article/e6e9a59ebac1837bPharmaRadar360en2026-04-22T10:00:00.000ZTop Drugs at Risk of Supply Shortages: Reporthttps://www.pharmaradar360.com/article/17a42e4814c13f7aPharmaRadar360en2026-04-22T10:00:00.000ZHow Compounding Has Become a Permanent Bridge for Healthcare Access: Q&A with Dr. Nicole Snowhttps://www.pharmaradar360.com/article/27faad91f228325bPharmaRadar360en2026-04-22T10:00:00.000ZAmneal Agrees to Acquire Kashiv BioSciences to Create Global Biosimilar Leader; Reports Strong Preliminary First Quarter 2026 Financial Results and Raises FY2026 Standalone Guidancehttps://www.pharmaradar360.com/article/8a164d49474ce974PharmaRadar360en2026-04-22T09:44:08.000ZMSD and Eisai’s RCC combination regimens fail to meet Phase III trial endpointshttps://www.pharmaradar360.com/article/0a9bff16ddb576edPharmaRadar360en2026-04-22T09:36:40.000Z#Move4Maties: Moving together to help students succeedhttps://www.pharmaradar360.com/article/b594737f2caaf702PharmaRadar360en2026-04-22T09:31:46.000ZBioAegis and Prenosis partner for inflammatory disease therapieshttps://www.pharmaradar360.com/article/28c5b0e206fcc3c7PharmaRadar360en2026-04-22T09:22:03.000ZNy strategi på gång för vården fram till 2040https://www.pharmaradar360.com/article/45d82bc88b11b525PharmaRadar360en2026-04-22T09:20:07.000ZESCMID Global 2026: real-world evidence of nirsevimab resistancehttps://www.pharmaradar360.com/article/5e48e6c1e2e1aab4PharmaRadar360en2026-04-22T09:05:24.000ZAntigen‑Stabilized Nanobody Probes Enable On‑Demand, Multicolor Protein Imaginghttps://www.pharmaradar360.com/article/8d45b6453c033a9dPharmaRadar360en2026-04-22T09:00:26.000ZMetagenomic software advance boosts research into microbial diversityhttps://www.pharmaradar360.com/article/326f1b08916591c6PharmaRadar360en2026-04-22T09:00:00.000ZApproximately half a million post-9/11 U.S. veterans had high blood pressurehttps://www.pharmaradar360.com/article/a554f0b9335995c8PharmaRadar360en2026-04-22T09:00:00.000ZAlrededor de medio millón de veteranos estadounidenses del período posterior al 11-S sufrían de presión arterial altahttps://www.pharmaradar360.com/article/71df236b8a963b6dPharmaRadar360en2026-04-22T08:01:17.000ZThe definitive infrastructure for modern drug developmenthttps://www.pharmaradar360.com/article/2738d289d9451bc3PharmaRadar360en2026-04-22T07:58:20.000ZThe definitive infrastructure for modern drug developmenthttps://www.pharmaradar360.com/article/38f4c39fa0f77a4fPharmaRadar360en2026-04-22T07:44:53.000ZOpiskelijoiden tietoja kerätty luvatta, Moodlen kurssien osallistujalistat toistaiseksi piilotettuhttps://www.pharmaradar360.com/article/1f910787318c4143PharmaRadar360en2026-04-22T07:40:39.000ZRoche reports Phase III METEOROID study results for MOGADhttps://www.pharmaradar360.com/article/8f3c67625d435b77PharmaRadar360en2026-04-22T07:36:00.000ZUpdate for LEGEhttps://www.pharmaradar360.com/article/cca17ddb907d70abPharmaRadar360en2026-04-22T07:35:53.000ZHealth Canada approves Biocon’s two denosumab biosimilarshttps://www.pharmaradar360.com/article/d39ccdebb63a3034PharmaRadar360en2026-04-22T07:30:00.000Z藤枝工場の低・中分子合成原薬製造棟「FJ3」、国際製薬技術協会（ISPE）の「2026 Facility of the Year Awards」をHonorable Mention部門で受賞https://www.pharmaradar360.com/article/abd7ad3dcd8e5f92PharmaRadar360en2026-04-22T07:30:00.000ZFJ3, API Manufacturing Building for Small Molecule and Macrocyclic Peptide Drugs at the Fujieda Plant, Receives the 2026 Facility of the Year Awards from ISPE in the Honorable Mention Categoryhttps://www.pharmaradar360.com/article/7b5bd9129ba24039PharmaRadar360en2026-04-22T07:23:03.000ZCreating the future of medical technology in South Africahttps://www.pharmaradar360.com/article/543ebf9d35c899e2PharmaRadar360en2026-04-22T07:07:52.000ZHelsingin yliopiston kansainvälisiin maisteriohjelmiin 3 739 hakijaahttps://www.pharmaradar360.com/article/4ded9837399c5303PharmaRadar360en2026-04-22T07:01:26.000ZΑνάκληση της Άδειας Χονδρικής πώλησης φαρμάκων για Ανθρώπινη Χρήση στο πρατήριο της εταιρείας ΕΝΟΡΑΣΙΣ ΑΕhttps://www.pharmaradar360.com/article/4e1c7e7bab60c6c0PharmaRadar360en2026-04-22T07:00:00.000ZDr. Davies: ‘Our best work still lies in front of us’https://www.pharmaradar360.com/article/77662a8a41262451PharmaRadar360en2026-04-22T06:58:00.000ZFor the Greater Good starts at noon todayhttps://www.pharmaradar360.com/article/2920e84e24d0ef12PharmaRadar360en2026-04-22T06:57:19.000ZΑνάκληση των παρτίδων 17270129, 17363725, 17385132, του φαρμακευτικού προϊόντος VISIPAQUE INJ.SOL 625 MG(320MG I)/ML BTx1 USB BOTTLE x 100mlhttps://www.pharmaradar360.com/article/2978de5dc6637161PharmaRadar360en2026-04-22T06:56:00.000ZAAMC president delivers message of hope, determination amid changehttps://www.pharmaradar360.com/article/b18a4e9c6e4e2484PharmaRadar360en2026-04-22T06:54:00.000ZNew mural provides eye-catching historical contexthttps://www.pharmaradar360.com/article/d0f53081c202b4f7PharmaRadar360en2026-04-22T06:30:38.000ZCarea adds miscarriage support feature to maternal health apphttps://www.pharmaradar360.com/article/83d4631508761050PharmaRadar360en2026-04-22T06:30:00.000Zロシュ社によるミエリンオリゴデンドロサイト糖タンパク質抗体関連疾患（MOGAD）に対するエンスプリングの新たなデータ発表についてhttps://www.pharmaradar360.com/article/3bdf3292407a4ce8PharmaRadar360en2026-04-22T06:30:00.000ZRoche’s Announcement Regarding New Data of Enspryng for Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOGAD)https://www.pharmaradar360.com/article/48917047c1cee4caPharmaRadar360en2026-04-22T06:00:36.000ZΈντυπα & Διαδικασίες Τμήματος Τιμολόγησηςhttps://www.pharmaradar360.com/article/9b8ae7414f95860aPharmaRadar360en2026-04-22T06:00:00.000ZFebbre nei bambini: il Pronto Soccorso del Policlinico di Milano primo in Lombardia a eseguire il test rapido per capire se è batterica o viralehttps://www.pharmaradar360.com/article/eb2e3a0b7b356ccaPharmaRadar360en2026-04-22T05:05:39.000ZA New Chapter for Children with pLGGhttps://www.pharmaradar360.com/article/6cd21b9b188287c5PharmaRadar360en2026-04-22T05:01:10.000ZFrom Brain Implant to Lifelong Companion: Michel Maharbiz Unveils Epia Neurohttps://www.pharmaradar360.com/article/2a04558b92d4329bPharmaRadar360en2026-04-22T04:51:12.000ZTwo common drugs may reverse fatty liver disease, study findshttps://www.pharmaradar360.com/article/75e71e4562f227aePharmaRadar360en2026-04-22T04:47:25.000ZNeuer Ansatz gegen Abwehrreaktion nach Stammzelltransplantationhttps://www.pharmaradar360.com/article/a3c05d96249b6515PharmaRadar360en2026-04-22T04:33:00.000ZNorth Texas leaders unite to kick off 2026 American Heart Association Heart Walkhttps://www.pharmaradar360.com/article/e070705a0b39c798PharmaRadar360en2026-04-22T04:08:37.000Z2026年度 プロトコール作成セミナー開催のお知らせ（6/6開催）https://www.pharmaradar360.com/article/16b4b82871f796dcPharmaRadar360en2026-04-22T04:08:23.000Z2026年度 プロトコール作成セミナー関連講義開催のお知らせ（5/18、22開催）https://www.pharmaradar360.com/article/bf7407f185e63e68PharmaRadar360en2026-04-22T04:08:17.000ZRadiologists collect $90M in research funding from imaging industry, with overall share of pie fallinghttps://www.pharmaradar360.com/article/ab47f4020e59a82ePharmaRadar360en2026-04-22T03:55:23.000ZFDA’s Pep(tide) Rally! What Compounders and Industry Need to Know (Post 2 of 2)https://www.pharmaradar360.com/article/75741390d8154210PharmaRadar360en2026-04-22T03:55:08.000ZA Time to Cast Away Meds…https://www.pharmaradar360.com/article/4866e7a321749ce9PharmaRadar360en2026-04-22T03:51:51.000ZQuality Director of Operationshttps://www.pharmaradar360.com/article/d0ec0c412bbe5a09PharmaRadar360en2026-04-22T03:51:45.000ZDirector, Scientific Advisor, Antibody Discoveryhttps://www.pharmaradar360.com/article/5898c1ce1cb77ad3PharmaRadar360en2026-04-22T03:51:42.000ZDirector, Scientific Advisor, In Vivo Pharmacologyhttps://www.pharmaradar360.com/article/f7848afce73f9ea1PharmaRadar360en2026-04-22T03:50:44.000ZRadiology vendors merge, creating platform that manages medical imaging for nearly 6M Americanshttps://www.pharmaradar360.com/article/691cab6d160246fcPharmaRadar360en2026-04-22T03:43:18.000ZGE HealthCare touts international expansion of its partnership with RadNethttps://www.pharmaradar360.com/article/242565ea4c96a019PharmaRadar360en2026-04-22T02:28:31.000Z2026年度 第2回 臨床研究講習会開催のお知らせ（5/14開催）https://www.pharmaradar360.com/article/f71211351b610a23PharmaRadar360en2026-04-22T02:24:01.000Z【日本臨床免疫学会】各種教育事業のご案内https://www.pharmaradar360.com/article/c5d3ec4970b87edcPharmaRadar360en2026-04-22T00:00:00.000ZDeepFAN, a transformer-based model for human–artificial intelligence collaborative assessment of incidental pulmonary nodules in CT scans: a multireader, multicase trialhttps://www.pharmaradar360.com/article/5289d62745716a6dPharmaRadar360en2026-04-22T00:00:00.000ZThe ghost of tuberculosis pasthttps://www.pharmaradar360.com/article/c6d5c71656b6b0adPharmaRadar360en2026-04-22T00:00:00.000ZThe future of diagnostics in Africahttps://www.pharmaradar360.com/article/2b54814ea3b907ecPharmaRadar360en2026-04-22T00:00:00.000ZSynthetic biology’s uncertain regulatory future in the wake of Loper Bright Enterprises v. Raimondohttps://www.pharmaradar360.com/article/9fd25fbde68156ddPharmaRadar360en2026-04-22T00:00:00.000ZDeeper is not always better in plasma proteomicshttps://www.pharmaradar360.com/article/b0c65c772d986f08PharmaRadar360en2026-04-22T00:00:00.000ZReference-free discovery with barcoded single-cell sequencinghttps://www.pharmaradar360.com/article/996c708391570e25PharmaRadar360en2026-04-22T00:00:00.000Z‘Staggering’ number of people believe unproven claims about vaccines, raw milk and morehttps://www.pharmaradar360.com/article/2ca69e7efca3b254PharmaRadar360en2026-04-22T00:00:00.000ZThe misunderstood sex chromosome: how X affects your healthhttps://www.pharmaradar360.com/article/e23a298fc7c47c5dPharmaRadar360en2026-04-22T00:00:00.000Znatco records %e2%82%b9705 4 crore consolidated revenue and %e2%82%b9151 3 crore of profit after tax for q3fy26https://www.pharmaradar360.com/article/ae45fb313aded55ePharmaRadar360en2026-04-22T00:00:00.000Znatco records %e2%82%b91463 crore consolidated revenue and %e2%82%b9517 9 crore of profit after tax for q2fy26https://www.pharmaradar360.com/article/6404fa7c9a9887cdPharmaRadar360en2026-04-22T00:00:00.000Znatco receives tentative approval for erdafitinib tablets generic of balversa from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/043468112677b796PharmaRadar360en2026-04-22T00:00:00.000Znatco receives approval from central drug standard control organisation cdsco for semaglutide in indiahttps://www.pharmaradar360.com/article/18654d55dc2ac49aPharmaRadar360en2026-04-22T00:00:00.000Znatco pharma limited api unit in chennai receives establishment inspection report eir from u s fdahttps://www.pharmaradar360.com/article/0f6023c3b526b332PharmaRadar360en2026-04-22T00:00:00.000Znatco pharma launches semaglutide generic injection multi dose vials in india at the most affordable price starting from mrp inr 1290https://www.pharmaradar360.com/article/002832a8ef7a0a40PharmaRadar360en2026-04-22T00:00:00.000Znatco announces launch of pomalidomide capsules generic of pomalyst in the u s markethttps://www.pharmaradar360.com/article/f11b28169b0704c2PharmaRadar360en2026-04-22T00:00:00.000Znatco announces launch of its everolimus tablets 1 mg generic of zortresshttps://www.pharmaradar360.com/article/29b673dab6ac7d6fPharmaRadar360en2026-04-22T00:00:00.000Zlegal update regarding risdiplamhttps://www.pharmaradar360.com/article/5c40c6b2e9163dc1PharmaRadar360en2026-04-22T00:00:00.000Zintimation under regulation 30 of sebi listing obligations and disclosure requirements regulations 2015 2https://www.pharmaradar360.com/article/65099171952ae713PharmaRadar360en2026-04-22T00:00:00.000Zdisclosure under regulation 30 of the sebi listing obligations and disclosure requirements regulations 2015https://www.pharmaradar360.com/article/3adde5f6e199459bPharmaRadar360en2026-04-22T00:00:00.000Zadcock ingram completes delisting from jse natco pharma acquires 35 75 stakehttps://www.pharmaradar360.com/article/10158a77aefea345PharmaRadar360en2026-04-22T00:00:00.000Z6203https://www.pharmaradar360.com/article/a5b431d9846c569cPharmaRadar360en2026-04-22T00:00:00.000ZHome pagehttps://www.pharmaradar360.com/article/376cf5c230c08087PharmaRadar360en2026-04-22T00:00:00.000ZUnited Therapeutics Corporation to Report First Quarter 2026 Financial Results Before Market Open on Wednesday, May 6, 2026https://www.pharmaradar360.com/article/d2c574e9159c44ecPharmaRadar360en2026-04-21T23:15:15.000Z#AAN26: Roche’s multiple sclerosis pill delays relapse, but liver toxicity could need monitoringhttps://www.pharmaradar360.com/article/1e80eeeba7a4ad89PharmaRadar360en2026-04-21T23:15:00.000ZRoche’s fenebrutinib significantly reduced relapses versus standard of care to approximately one every 17 years in RMShttps://www.pharmaradar360.com/article/8bc3783067d5daccPharmaRadar360en2026-04-21T22:35:00.000ZTwo MIT alumnae named 2026 Gates Cambridge Scholarshttps://www.pharmaradar360.com/article/53bccf02ece563edPharmaRadar360en2026-04-21T21:32:17.000ZIntercepting Oral Cancer, Sparing Surgery, Preserving Quality of Lifehttps://www.pharmaradar360.com/article/43d224474ac693dePharmaRadar360en2026-04-21T21:31:23.000ZZymeworks Presents New Phase 1 Data for ZW191, a Folate Receptor Alpha-Targeting ADC at AACR Annual Meeting 2026https://www.pharmaradar360.com/article/1cb9ae6e0928443ePharmaRadar360en2026-04-21T21:15:27.000ZBaseCase® Turn Evidence into Decisions – at Scalehttps://www.pharmaradar360.com/article/2941400669e7b8bdPharmaRadar360en2026-04-21T20:52:00.000ZTwo Minnesota changemakers recognized for leading efforts to end cardiovascular diseasehttps://www.pharmaradar360.com/article/0d8404cfb4e7e8d1PharmaRadar360en2026-04-21T20:47:50.000ZBuilding a More Sustainable Cold Chain Through Intelligence, Resilience, and Accountabilityhttps://www.pharmaradar360.com/article/5510d1cf38195756PharmaRadar360en2026-04-21T20:21:55.000ZMedicare indefinitely delays pilot plan to cover weight loss drugshttps://www.pharmaradar360.com/article/a5b2492089525138PharmaRadar360en2026-04-21T20:20:47.000ZInterventional radiologist launches AI-powered, IR-specific decision support platformhttps://www.pharmaradar360.com/article/a25301fbce030786PharmaRadar360en2026-04-21T20:05:32.000ZAmerican College of Radiology offers cybersecurity resourceshttps://www.pharmaradar360.com/article/0ce68d4723d5ecb1PharmaRadar360en2026-04-21T19:57:38.000ZSatralizumab Significantly Reduces Risk of Attacks in Relapsed MOGADhttps://www.pharmaradar360.com/article/0a01a2174920e602PharmaRadar360en2026-04-21T19:49:04.000ZAlzheimer’s Linked to Cancer Mutations in Brain Immune Cellshttps://www.pharmaradar360.com/article/73c565c3f11e51c9PharmaRadar360en2026-04-21T19:49:00.000ZNWSL’S Racing Louisville FC participate in Hands-Only CPR and AED traininghttps://www.pharmaradar360.com/article/f8c308f15b58d425PharmaRadar360en2026-04-21T19:47:45.000ZRadiopharmaceutical manufacturer secures $30M to bolster domestic isotope productionhttps://www.pharmaradar360.com/article/5e3e3d8d16c45782PharmaRadar360en2026-04-21T19:39:33.000ZAACR 2026: Lung Cancer Immunotherapy Response Predicted by Pathomics AI Modelhttps://www.pharmaradar360.com/article/69fa1e8330972226PharmaRadar360en2026-04-21T19:31:09.000ZCosmo Pharma Eyes 2027 NDA for Baldness Candidate After Positive Phase III 12-Month Datahttps://www.pharmaradar360.com/article/2b6295b7f6ca0230PharmaRadar360en2026-04-21T19:24:00.000ZBridging the Gap: How Housing Status and Race Shape Cancer Screening Disparitieshttps://www.pharmaradar360.com/article/c081b103dbaa7350PharmaRadar360en2026-04-21T19:19:34.000ZPharmaceutical Executive Daily: UnitedHealth Raises Full-Year Profit Forecasthttps://www.pharmaradar360.com/article/402e37fba90dc336PharmaRadar360en2026-04-21T19:18:52.000ZFDA Approves Once-Daily HIV Regimen Combining Doravirine and Islatravirhttps://www.pharmaradar360.com/article/421ee8bc83419032PharmaRadar360en2026-04-21T19:15:47.000ZNanoplasty®-Dr. Lonabaughhttps://www.pharmaradar360.com/article/be0e7be9258bc0c0PharmaRadar360en2026-04-21T19:05:00.000ZLocal 6th grade teacher raises awareness and funds to end women’s No. 1 health threathttps://www.pharmaradar360.com/article/920be0f6a15ea4acPharmaRadar360en2026-04-21T18:45:47.000ZRFK Jr. says China is 'eating our lunch' in biotech advanceshttps://www.pharmaradar360.com/article/b4eb83f14278d2f0PharmaRadar360en2026-04-21T18:41:31.000ZA closer look at Utah’s healthcare AI strategyhttps://www.pharmaradar360.com/article/094f5389317ec424PharmaRadar360en2026-04-21T18:38:31.000ZFundación internacional Friends UC se une al sueño de transformar Chile en su visita anualhttps://www.pharmaradar360.com/article/3f638111401749c8PharmaRadar360en2026-04-21T18:11:00.000ZFDA Approves Merck’s Once-Daily IDVYNSO™ (doravirine/islatravir)https://www.pharmaradar360.com/article/62e9b035f2c6294dPharmaRadar360en2026-04-21T18:01:54.000ZMerck's Welireg combo fails in first-line kidney cancerhttps://www.pharmaradar360.com/article/d52800134a6f82c1PharmaRadar360en2026-04-21T18:00:00.000ZThe Gold Standard: Why Dual-Credentialing Is the Backbone of Pharmacy Safetyhttps://www.pharmaradar360.com/article/95ba034603d0a28bPharmaRadar360en2026-04-21T17:58:32.000ZLa UNLP profundiza su agenda estratégica y vuelve a reunir a especialistas en Tierras Rarashttps://www.pharmaradar360.com/article/71237105aa72f280PharmaRadar360en2026-04-21T17:58:00.000ZNovartis narrows focus for anticoagulant after failure to best Eliquis in phase 3 trialhttps://www.pharmaradar360.com/article/c5a3f098215d4a03PharmaRadar360en2026-04-21T17:23:31.000ZUnitedHealth breaks down how it plans to spend $1.5B on AIhttps://www.pharmaradar360.com/article/c21ada0426194af4PharmaRadar360en2026-04-21T17:15:53.000ZLa UNLP presente en la primera jornada de “Activá las Alertas”: un ciclo de charlas para concientizar sobre riesgos digitales y ludopatíahttps://www.pharmaradar360.com/article/10853d3ddfb746d4PharmaRadar360en2026-04-21T17:13:19.000ZAlcami to Acquire Contract Packaging Organization Tjoapackhttps://www.pharmaradar360.com/article/e3ff5ff6fecbd634PharmaRadar360en2026-04-21T17:09:01.000ZScaling AI in Pharma Requires More Than Algorithmshttps://www.pharmaradar360.com/article/33966654a026fad9PharmaRadar360en2026-04-21T17:06:26.000ZNavigating with Excellence: The Multi-Faceted Service Lines of Precision Logisticshttps://www.pharmaradar360.com/article/45fd647246017fcaPharmaRadar360en2026-04-21T17:05:00.000ZDeficiency in Care: Underutilization of Intravenous Iron for Acute Heart Failurehttps://www.pharmaradar360.com/article/b9bc062d8fca5464PharmaRadar360en2026-04-21T17:04:51.000ZWhat Does it Take to Scale Cell and Gene Therapies from Discovery to Commercializationhttps://www.pharmaradar360.com/article/1613b9d8f288ed93PharmaRadar360en2026-04-21T17:01:03.000ZFDA approves once-daily HIV pill from Merckhttps://www.pharmaradar360.com/article/5915f7578e3f49c3PharmaRadar360en2026-04-21T16:54:00.000ZCommunity Health Systems reports low volumes, earnings dip for Q1 2026https://www.pharmaradar360.com/article/6eb6b50972e9dcb1PharmaRadar360en2026-04-21T16:53:05.000ZWhy Are Women More Likely to Develop MS? New Proteomics Study Finds Clueshttps://www.pharmaradar360.com/article/468e9837db26e86fPharmaRadar360en2026-04-21T16:52:53.000ZTempus Next Pathways unlocked critical insights into the aNSCLC patient journey with Bristol Myers Squibb (BMS)https://www.pharmaradar360.com/article/b7c36e9df24c06d8PharmaRadar360en2026-04-21T16:45:47.000ZBreaking Down the U.S. Global Health Budget by Program Areahttps://www.pharmaradar360.com/article/561f8f1515ce7cd7PharmaRadar360en2026-04-21T16:35:57.000ZBeating transplant challengeshttps://www.pharmaradar360.com/article/9e657631fd417cb1PharmaRadar360en2026-04-21T16:25:00.000ZNew poll shows strong region-wide support for SkyTrain extension to UBChttps://www.pharmaradar360.com/article/102e6d0ca47c4727PharmaRadar360en2026-04-21T16:20:00.000ZIntegrating Microbiome and Genomics With AI Uncovers New Patterns in Early-Onset Colorectal Cancerhttps://www.pharmaradar360.com/article/dc52deb7a777dd62PharmaRadar360en2026-04-21T16:06:41.000ZUniversity of Minnesota Crookston's John Loegering receives award from Minnesota Chapter of Wildlife Societyhttps://www.pharmaradar360.com/article/59234eb9754e0d61PharmaRadar360en2026-04-21T16:05:45.000ZUniversity of Minnesota students partner with NASA to create innovative space suit designshttps://www.pharmaradar360.com/article/f5e1f18e65daa08fPharmaRadar360en2026-04-21T16:00:48.000Z6° Jornadas sobre prácticas docentes en la Universidad Públicahttps://www.pharmaradar360.com/article/87b7914c3eba34b1PharmaRadar360en2026-04-21T16:00:26.000ZA New Doctor of Pharmacy Pathwayhttps://www.pharmaradar360.com/article/59b859716c4b77f5PharmaRadar360en2026-04-21T16:00:00.000ZUpstream Risks: How Global Trade Disruptions Could Impact Medication Supplyhttps://www.pharmaradar360.com/article/6c9335cd5059d1d1PharmaRadar360en2026-04-21T16:00:00.000ZAAN 2026: Expert Insight on Cemdisiran’s Role in Simplifying gMG Care Through Subcutaneous Quarterly Dosinghttps://www.pharmaradar360.com/article/af1b7798749d96f1PharmaRadar360en2026-04-21T16:00:00.000ZXuanzhu shares dip despite phase III ALK inhibitor datahttps://www.pharmaradar360.com/article/abe45b24beec76ebPharmaRadar360en2026-04-21T16:00:00.000ZBiogen amasses full felzartamab rights with $850M TJ dealhttps://www.pharmaradar360.com/article/89ee9edc9fd1e810PharmaRadar360en2026-04-21T15:54:33.000ZPancreatic Cancer mRNA Vaccine Shows Promising Results in Early Clinical Trialhttps://www.pharmaradar360.com/article/8caababfbdd8c5f3PharmaRadar360en2026-04-21T15:51:45.000ZHongos: el superalimento que pide precauciónhttps://www.pharmaradar360.com/article/dc51ba6279859663PharmaRadar360en2026-04-21T15:51:17.000ZTauber inauguró la obra de remodelación integral del imponente edificio del INIFTAhttps://www.pharmaradar360.com/article/3034b4658b55b7dfPharmaRadar360en2026-04-21T15:50:44.000ZTauber recorrió las obras finalizadas del primer módulo de viviendas del barrio estudiantilhttps://www.pharmaradar360.com/article/52a8209230c1c7caPharmaRadar360en2026-04-21T15:49:56.000ZLa UNLP firmó un convenio con el Colegio de Escribanos de la provincia de Buenos Aireshttps://www.pharmaradar360.com/article/5bc7e7cdd3f9b1afPharmaRadar360en2026-04-21T15:48:45.000ZCurso de Armado y Reparación de PC para estudiantes de la UNLPhttps://www.pharmaradar360.com/article/db1ea39a30d2adc4PharmaRadar360en2026-04-21T15:46:15.000ZLa UNLP lanzó el concurso “Narremos Memoria” en el Colegio Nacionalhttps://www.pharmaradar360.com/article/bb490a445cac78fcPharmaRadar360en2026-04-21T15:45:08.000ZMedicaid Waiver Tracker: Approved and Pending Section 1115 Waivers by Statehttps://www.pharmaradar360.com/article/eee11c9a0be29289PharmaRadar360en2026-04-21T15:45:00.000ZRoche’s ENSPRYNG (satralizumab) reduces risk of relapses by 68% demonstrating potential to become first treatment for MOGADhttps://www.pharmaradar360.com/article/6a1f708aac1e64b1PharmaRadar360en2026-04-21T15:44:11.000ZCanada’s Hardest Problems Demand a Different Kind of Science. Here’s How We Work.https://www.pharmaradar360.com/article/6ff2075d4bebf9afPharmaRadar360en2026-04-21T15:42:47.000ZUn « Hub prévention » innovant pour faire des patients les acteurs de leur prise en chargehttps://www.pharmaradar360.com/article/3bba67ba0624e67aPharmaRadar360en2026-04-21T15:40:19.000ZLa UNLP distinguió con el título de Doctor Honoris Causa al artista platense César Paternostohttps://www.pharmaradar360.com/article/b2a31db281fc9079PharmaRadar360en2026-04-21T15:38:16.000Z'It's just the beginning' for pancreatic cancer's long-awaited breakthroughhttps://www.pharmaradar360.com/article/82a50922b6b73bd2PharmaRadar360en2026-04-21T15:20:59.000ZCarvykti shows promise before multiple myeloma; two megarounds; AstraZeneca wins twicehttps://www.pharmaradar360.com/article/34c15f3256100dc9PharmaRadar360en2026-04-21T15:19:00.000ZRacing toward first FDA nod for autoimmune CAR-T, Kyverna bolsters lead with full SPS datasethttps://www.pharmaradar360.com/article/b6268973075353e1PharmaRadar360en2026-04-21T15:16:53.000ZClinical Trial Participation: How Can We Make it More Feasible?https://www.pharmaradar360.com/article/901c7182281ceeccPharmaRadar360en2026-04-21T15:09:59.000ZCancer Cell - Une étude française perce le mécanisme d’action d’un médicament innovant chez des patients atteints d’un cancer du poumon au stade avancéhttps://www.pharmaradar360.com/article/21bf59f6f6148264PharmaRadar360en2026-04-21T15:08:17.000ZESCMID Global 2026: repeat vaccination with mRNA-1010 safe and effectivehttps://www.pharmaradar360.com/article/533883e6471bb58aPharmaRadar360en2026-04-21T15:05:34.000ZU7+ Summit 2026: Universities Help Shape the G7 Agendahttps://www.pharmaradar360.com/article/4d039e70e85f83e0PharmaRadar360en2026-04-21T15:00:00.000ZWCG to Acquire The Contract Network, Extending ClinSphere’s AI-Driven Site Enablement Capabilities Across Study Start-Uphttps://www.pharmaradar360.com/article/8b0ea0ba2a0fad47PharmaRadar360en2026-04-21T15:00:00.000ZRIKEN invests into SAIMEMORY Corphttps://www.pharmaradar360.com/article/cc5c4c97e8687559PharmaRadar360en2026-04-21T15:00:00.000ZThe Rise of Peptides: Innovation, Safety, and Clinical Realityhttps://www.pharmaradar360.com/article/1b670ddf15d0e80fPharmaRadar360en2026-04-21T14:51:01.000ZEfficacy of Catheter Ablation in Atrial Fibrillation Patients With Pulmonary Hypertensionhttps://www.pharmaradar360.com/article/375ba5ef73b55edcPharmaRadar360en2026-04-21T14:48:55.000ZCustomized Sheath Modification for Bachmann Bundle Area Pacing With a Stylet‐Driven Leadhttps://www.pharmaradar360.com/article/e9baed2d4858a72fPharmaRadar360en2026-04-21T14:46:00.000ZMerck amps up presence in HIV treatment market with FDA nod for novel combo pill Idvynsohttps://www.pharmaradar360.com/article/941004507c08dae9PharmaRadar360en2026-04-21T14:44:53.000ZImpact of Dual‐Chamber Leadless Pacemakers on Valvular Function: Early to Mid‐Term Follow‐Up Studyhttps://www.pharmaradar360.com/article/a2044be020d8e72aPharmaRadar360en2026-04-21T14:39:14.000ZEarly Mobilization After Pacemaker Implantation: Toward Optimized Patient Selection and Contemporary Device Strategieshttps://www.pharmaradar360.com/article/fcbcdb1549171f63PharmaRadar360en2026-04-21T14:34:42.000ZIan Playford reappointed as Non-Executive Directorhttps://www.pharmaradar360.com/article/03a1b0e7c996997fPharmaRadar360en2026-04-21T14:30:00.000ZAAN 2026: Why Alzheimer Disease Brain Stimulation Trials Have Had Mixed Results—And How a New Memory Network Could Fix Thathttps://www.pharmaradar360.com/article/da715139730edaacPharmaRadar360en2026-04-21T14:25:21.000ZTwo Years After Opening, Intermountain Health Primary Children’s Hospital - Miller Family Campus in Lehi is Expanding to Meet Growing Demand for Pediatric Carehttps://www.pharmaradar360.com/article/9d47f6f4cb38cdb3PharmaRadar360en2026-04-21T14:23:13.000ZThe real cost of waiting to build your QMShttps://www.pharmaradar360.com/article/56220e8aa9cf782bPharmaRadar360en2026-04-21T14:23:00.000Z'Don't be a wimp,' Mark Cuban tells lawmakers hesitant to break up PBMshttps://www.pharmaradar360.com/article/649ed95dc6b9d636PharmaRadar360en2026-04-21T14:22:54.000ZDelpharm Tours wzmacnia swoją wiedzę specjalistyczną w zakresie sterylnego napełniania zgodnie z załącznikiem 1.https://www.pharmaradar360.com/article/abfe80b777709f86PharmaRadar360en2026-04-21T14:21:40.000ZDelpharm Tours rafforza la propria competenza nel riempimento sterile in conformità con l'Allegato 1.https://www.pharmaradar360.com/article/ef3ba965fde773fdPharmaRadar360en2026-04-21T14:20:23.000ZDelpharm Tours strengthens its expertise in sterile filling in accordance with Annex 1.https://www.pharmaradar360.com/article/d9c33dd47845b962PharmaRadar360en2026-04-21T14:18:41.000ZSome Cancer Drugs Disrupt Taste by Changing the Cells Inside Taste Buds, Study Showshttps://www.pharmaradar360.com/article/e51117a8c94c4d90PharmaRadar360en2026-04-21T14:17:27.000ZDelpharm Tours renforce son expertise en remplissage stérile conformément à l'Annexe 1.https://www.pharmaradar360.com/article/c8f98a5ecf425141PharmaRadar360en2026-04-21T14:15:00.000ZPREVENT Risk Calculator Maintains Accuracy in Real-World EHR Settings Despite Missing Datahttps://www.pharmaradar360.com/article/803ca178f3ea5f9aPharmaRadar360en2026-04-21T14:04:43.000ZUnitedHealth Raises Profit Forecast Following Improved First Quarter Resultshttps://www.pharmaradar360.com/article/3049bbfe0841afc9PharmaRadar360en2026-04-21T14:01:36.000ZParadigm Health debuts post-marketing study tool for routine care integrationhttps://www.pharmaradar360.com/article/da44c5ddefe29b0dPharmaRadar360en2026-04-21T14:00:00.000ZResearchers Identify Differences in Antiseizure Medication Prescribing Patterns in Pre-, Postmenopausal Women With Epilepsyhttps://www.pharmaradar360.com/article/d1e47dab9da411e4PharmaRadar360en2026-04-21T14:00:00.000ZThe selfish ribosomehttps://www.pharmaradar360.com/article/4ae4561a6e919ecbPharmaRadar360en2026-04-21T14:00:00.000ZGenomic and functional adaptations in the guanylate-binding protein 5 highlight specificities of bat antiviral innate immunityhttps://www.pharmaradar360.com/article/bd11b10172da6b12PharmaRadar360en2026-04-21T13:55:00.000ZMathematical modelling to move science on schistosomiasis forwardhttps://www.pharmaradar360.com/article/1b57bc98cca738a4PharmaRadar360en2026-04-21T13:40:31.000ZFormer cancer patient will graduate from nursing schoolhttps://www.pharmaradar360.com/article/1bf698519ea9bbd2PharmaRadar360en2026-04-21T13:27:34.000ZStepping Into Pharma: Navigating the Shift From Pharmacy Classroom to Corporate Settinghttps://www.pharmaradar360.com/article/4f1727571b4c5a10PharmaRadar360en2026-04-21T13:24:05.000ZAllogene Therapeutics Expands Pivotal Phase 2 ALPHA3 Trial to South Korea and Australiahttps://www.pharmaradar360.com/article/8ccbfc711e406630PharmaRadar360en2026-04-21T13:21:40.000ZTar Heels, now read thishttps://www.pharmaradar360.com/article/97a741fc3f42c519PharmaRadar360en2026-04-21T13:16:58.000ZLa UNLP busca recuperar canteras abandonadas en la provincia de Buenos Aireshttps://www.pharmaradar360.com/article/7c771fe1d6106bfbPharmaRadar360en2026-04-21T13:16:31.000ZGift of Life: St. Michael’s Hospital hits significant milestone with 50 living kidney transplants in one yearhttps://www.pharmaradar360.com/article/473f21716962dadePharmaRadar360en2026-04-21T13:13:17.000ZFernando Tauber recibió a autoridades de la Universidad de Zaragozahttps://www.pharmaradar360.com/article/78c4b8b8460d21cePharmaRadar360en2026-04-21T13:12:04.000ZHow can collaborative care help cancer patients?https://www.pharmaradar360.com/article/eaba5f70ca94e05fPharmaRadar360en2026-04-21T13:06:15.000ZDerecho a inventar: lecturas entre la verdad y la ficciónhttps://www.pharmaradar360.com/article/262ffdcb7bf7adc2PharmaRadar360en2026-04-21T13:05:10.000ZLa AEMPS establece los requisitos técnicos para el registro de medicamentos veterinarios no biológicoshttps://www.pharmaradar360.com/article/68e38d6d8379ee5cPharmaRadar360en2026-04-21T13:02:53.000ZLive Updates From the AACR Annual Meeting 2026: Tuesday, April 21https://www.pharmaradar360.com/article/8c68c120f0d90ce1PharmaRadar360en2026-04-21T13:00:38.000ZWhere Utah’s experiment with AI doctors is headed nexthttps://www.pharmaradar360.com/article/9db5b0cab94ec4b7PharmaRadar360en2026-04-21T12:59:35.000ZCompras y Contratacioneshttps://www.pharmaradar360.com/article/e6c1b0943b1f9dc8PharmaRadar360en2026-04-21T12:57:36.000ZMuestra fotográfica “Madres de plaza de mayo y la resistencia popular”https://www.pharmaradar360.com/article/ff1bb7012e70e39aPharmaRadar360en2026-04-21T12:53:18.000ZANMAT suspende la habilitación para la distribución interjurisdiccional de medicamentos de la firma GLOBAL PHARMA GROUP S.A.https://www.pharmaradar360.com/article/9859ecf1b24dfa32PharmaRadar360en2026-04-21T12:38:30.000ZMilliporeSigma Launches First Bio-Based Solvent Portfolio for High-Performance Liquid Chromatographyhttps://www.pharmaradar360.com/article/7ed7122c91c42df5PharmaRadar360en2026-04-21T12:38:18.000ZLópez Armengol participó de una cumbre de rectores de las grandes universidades de la regiónhttps://www.pharmaradar360.com/article/6200fdbd21234b57PharmaRadar360en2026-04-21T12:37:12.000ZAbrió la inscripción a los Talleres para estudianteshttps://www.pharmaradar360.com/article/ae429f62f91e7fbePharmaRadar360en2026-04-21T12:35:17.000ZCrown Bioscience & Turbine Partner to Connect AI-Driven Prediction With Organoid Validation in Translational Oncologyhttps://www.pharmaradar360.com/article/60a6e6f463e20336PharmaRadar360en2026-04-21T12:30:29.000Z‘Postcode lottery’ in robotic surgery access for patients, data showshttps://www.pharmaradar360.com/article/ee9305ec382aa5d1PharmaRadar360en2026-04-21T12:30:09.000ZTempus to Report First Quarter 2026 Financial Results on May 5https://www.pharmaradar360.com/article/fdd21bb815274567PharmaRadar360en2026-04-21T12:22:33.000Z2026 Massey Awards honor service to Carolinahttps://www.pharmaradar360.com/article/1abb84e365cdaddbPharmaRadar360en2026-04-21T12:00:00.000ZChaos in the heart and brainhttps://www.pharmaradar360.com/article/7231e005d526310bPharmaRadar360en2026-04-21T12:00:00.000ZHow to remove a metabolic tattoohttps://www.pharmaradar360.com/article/0974bf37384fa3e8PharmaRadar360en2026-04-21T12:00:00.000ZUnderstanding CSR vs Safety Narratives in Clinical Researchhttps://www.pharmaradar360.com/article/3654a4e9b556f37ePharmaRadar360en2026-04-21T12:00:00.000ZCharles River Highlights Effectiveness of VCGs in Toxicologyhttps://www.pharmaradar360.com/article/ac5c01f623de72d3PharmaRadar360en2026-04-21T11:54:42.000ZAACR 2026: A Video Update from San Diegohttps://www.pharmaradar360.com/article/88076b29acd4ef44PharmaRadar360en2026-04-21T11:33:00.000ZMerger to create nation's largest suicide prevention nonprofithttps://www.pharmaradar360.com/article/6acea541c11608d9PharmaRadar360en2026-04-21T11:29:20.000ZInformation about the criminal offence committed by a former employee of the University of Freiburghttps://www.pharmaradar360.com/article/662f5833d22bbdd3PharmaRadar360en2026-04-21T11:23:08.000ZSubmit your nominations for the Alumni prize for outstanding social involvement nowhttps://www.pharmaradar360.com/article/4deeff19966cc173PharmaRadar360en2026-04-21T11:23:00.000ZOz previews new plan to push states toward revalidating Medicaid providershttps://www.pharmaradar360.com/article/d03cd6864040a5a1PharmaRadar360en2026-04-21T10:58:00.000ZPfizer's strategy head Andrew Baum to step down following brief tenure: reportshttps://www.pharmaradar360.com/article/bab13df49c362e01PharmaRadar360en2026-04-21T10:58:00.000ZPfizer's strategy head Andrew Baum to step down following brief tenure: reportshttps://www.pharmaradar360.com/article/3c5d711868c1bdf3PharmaRadar360en2026-04-21T10:52:13.000ZHow do Forecasting Approaches and Methodologies Change Through the Product Lifecycle?https://www.pharmaradar360.com/article/c99e19485d625432PharmaRadar360en2026-04-21T10:51:49.000ZLa AEMPS desmiente el “callo solar” y recuerda la importancia de una exposición solar segurahttps://www.pharmaradar360.com/article/7dac9c55aaf56eeePharmaRadar360en2026-04-21T10:45:00.000ZMerck and Eisai Provide Update on Phase 3 LITESPARK-012 Trial Evaluating First-Line Combination Treatments for Certain Patients With Advanced Renal Cell Carcinoma (RCC)https://www.pharmaradar360.com/article/bd7f2b6559c0ae17PharmaRadar360en2026-04-21T10:41:42.000ZHow to tell complex stories in an engaging wayhttps://www.pharmaradar360.com/article/d7bfc89aeb7fd6f0PharmaRadar360en2026-04-21T10:41:05.000ZBoletín del Comité de Medicamentos de Uso Humano. Marzo de 2026https://www.pharmaradar360.com/article/2225ca33e6df64c9PharmaRadar360en2026-04-21T10:39:38.000ZUniverCities 2026 Conference: Call for papers open!https://www.pharmaradar360.com/article/4c7bfa045b83e5dcPharmaRadar360en2026-04-21T10:37:00.000ZRoche unpacks death imbalance, secondary endpoints in phase 3 multiple sclerosis trialshttps://www.pharmaradar360.com/article/18bd05fedfef3138PharmaRadar360en2026-04-21T10:33:59.000ZSoleno sold at a discount to Neurocrine due to dwindling European prospectshttps://www.pharmaradar360.com/article/00a278064277f363PharmaRadar360en2026-04-21T10:32:32.000ZTenvie doses first subject in Phase I TNV108 trial for peripheral neuropathieshttps://www.pharmaradar360.com/article/b3191f76e820ea87PharmaRadar360en2026-04-21T10:30:42.000ZFlagship’s latest startup aims to solve gene therapy’s thorniest technical challengehttps://www.pharmaradar360.com/article/b5f3a67237b09ce9PharmaRadar360en2026-04-21T10:30:07.000ZDigital Health Coffee Time Briefing ☕https://www.pharmaradar360.com/article/63d0b7535d0eeb6dPharmaRadar360en2026-04-21T10:20:00.000ZTortugas comes out of its shell with $106M to fund 4 phase 2-stage neuro drugs licensed from Asiahttps://www.pharmaradar360.com/article/22753fb2ea932978PharmaRadar360en2026-04-21T10:10:00.000ZCovera Health, Medmo combine to create end-to-end diagnostic imaging platformhttps://www.pharmaradar360.com/article/acdcc7015d9c7fc0PharmaRadar360en2026-04-21T10:06:00.000ZThe Oral GLP-1 Tracker: Following the launch trajectories of Lilly’s Foundayo, Novo’s Wegovy pillhttps://www.pharmaradar360.com/article/2cea1f39fe8431c0PharmaRadar360en2026-04-21T10:05:53.000ZEli Lilly doubles down on in vivo with $7bn Kelonia buyouthttps://www.pharmaradar360.com/article/610e44b0384400eePharmaRadar360en2026-04-21T10:01:00.000ZRay Therapeutics shines a light on $125M round targeting genetic eye therapyhttps://www.pharmaradar360.com/article/591f90bc57cafd04PharmaRadar360en2026-04-21T10:00:26.000ZPeople want reform of AI regulation in healthcare but not overhaulhttps://www.pharmaradar360.com/article/2790423ff56469c3PharmaRadar360en2026-04-21T10:00:00.000ZWhy KFF Is Launching a Podcast on the Business of Healthhttps://www.pharmaradar360.com/article/bf0ce0195ecf7f56PharmaRadar360en2026-04-21T09:56:00.000ZAstraZeneca eyes 5th Ultomiris indication after kidney disease trial winhttps://www.pharmaradar360.com/article/93596bbb25972a3dPharmaRadar360en2026-04-21T09:53:06.000ZData science: has AI solved drug discovery?https://www.pharmaradar360.com/article/13f28a4534941c04PharmaRadar360en2026-04-21T09:35:56.000ZPfizer and Astellas secure FDA priority review for Padcev MIBC combo therapyhttps://www.pharmaradar360.com/article/84a58b9e804169d0PharmaRadar360en2026-04-21T09:30:24.000ZAstraZeneca’s COPD drug gains third Phase III winhttps://www.pharmaradar360.com/article/d517012f51c4da0dPharmaRadar360en2026-04-21T09:25:00.000ZIn a Merck Litespark shocker, Welireg triplet misses the mark in first-line kidney cancerhttps://www.pharmaradar360.com/article/1099ea6a69db198bPharmaRadar360en2026-04-21T09:25:00.000ZIn a Merck Litespark shocker, Welireg triplet misses the mark in first-line kidney cancerhttps://www.pharmaradar360.com/article/ac0c8f3eef67aaeaPharmaRadar360en2026-04-21T09:21:08.000ZΕνημέρωση για την υποβολή των αιτημάτων τιμολόγησηςhttps://www.pharmaradar360.com/article/e3306265a9397fefPharmaRadar360en2026-04-21T09:21:01.000ZStatutory guidance: MHRA feeshttps://www.pharmaradar360.com/article/25d8738b5c3b9749PharmaRadar360en2026-04-21T08:46:00.000ZPulnovo Medical scores $100M in finance round led by Medtronichttps://www.pharmaradar360.com/article/390177994a77ea11PharmaRadar360en2026-04-21T08:34:42.000ZAsahi Kasei acquires German company Aicurishttps://www.pharmaradar360.com/article/74e8426fb4b21933PharmaRadar360en2026-04-21T08:19:52.000ZPaul-Martini-Preis für Professor Dr. Alwin Krämerhttps://www.pharmaradar360.com/article/e472a269e824a789PharmaRadar360en2026-04-21T08:07:52.000ZRecentring sites: The human factors slowing study start-up and how to resolve themhttps://www.pharmaradar360.com/article/7ee1e61e026bfbfbPharmaRadar360en2026-04-21T08:07:00.000ZUnitedHealth Group spotlights AI investments as part of operational turnaroundhttps://www.pharmaradar360.com/article/2aa7b1ad120ea92ePharmaRadar360en2026-04-21T08:00:04.000ZMarking and assessment boycotthttps://www.pharmaradar360.com/article/cae2edb8015be425PharmaRadar360en2026-04-21T07:55:00.000ZGroundbreaking bowel cancer trial follow-up shows zero relapseshttps://www.pharmaradar360.com/article/855222dafc1077e1PharmaRadar360en2026-04-21T07:54:00.000ZOverview of President Trump’s Executive Actions Impacting LGBTQ+ Healthhttps://www.pharmaradar360.com/article/d3139447e123e4e8PharmaRadar360en2026-04-21T07:45:11.000ZUniklinika plädieren für tragfähiges Gesamtkonzepthttps://www.pharmaradar360.com/article/204bd4cb1922c7fcPharmaRadar360en2026-04-21T07:40:31.000ZScientists discover hidden “master switch” driving skin cancer growth and immune escapehttps://www.pharmaradar360.com/article/9d08002a8fa2bc70PharmaRadar360en2026-04-21T07:39:00.000ZDeutsches Zentrum für Kinder- und Jugendgesundheit (DZKJ)https://www.pharmaradar360.com/article/19583cfb6926b4fcPharmaRadar360en2026-04-21T07:21:39.000ZInaugural Lecture: Prof Ashenafi Beyene Fantahttps://www.pharmaradar360.com/article/4ab4f34189905ad4PharmaRadar360en2026-04-21T07:17:00.000ZFoundation Medicine expands Bristol Myers Squibb collaboration with new diagnostic targethttps://www.pharmaradar360.com/article/37cbbf3de4ce07b4PharmaRadar360en2026-04-21T07:01:00.000ZECRI spins out healthcare supply chain division into Staritas, backed by PE firm Accel-KKRhttps://www.pharmaradar360.com/article/f25774ad94b6aec6PharmaRadar360en2026-04-21T07:00:00.000ZDr. Davies updates campus happenings, new process initiativehttps://www.pharmaradar360.com/article/9a5d4548db329797PharmaRadar360en2026-04-21T07:00:00.000ZRespiratory syncytial virus (RSV) in adults: risk and vaccinationhttps://www.pharmaradar360.com/article/06b71caadfd54d81PharmaRadar360en2026-04-21T07:00:00.000ZThree UC Davis leaders inducted as Fellows of the Association for Clinical and Translational Sciencehttps://www.pharmaradar360.com/article/cad8f0658d5ab553PharmaRadar360en2026-04-21T06:59:00.000ZKeith Olsen, PharmD, looks back fondly on his careerhttps://www.pharmaradar360.com/article/57b158c18c9cd949PharmaRadar360en2026-04-21T06:58:00.000ZUNMC resident’s rotation in India proves eye-openinghttps://www.pharmaradar360.com/article/64ceeaae391ec8ebPharmaRadar360en2026-04-21T06:54:00.000ZNew UNMC intranet design debuts todayhttps://www.pharmaradar360.com/article/8d133f03dfaeafe0PharmaRadar360en2026-04-21T06:30:47.000ZBuckinghamshire trust signs System C deal for AI-scribing in EPRhttps://www.pharmaradar360.com/article/69b9d44877a32b0dPharmaRadar360en2026-04-21T06:26:00.000ZUCB partners with Myasthenia Gravis Foundation of America on meal program targeting nutrition desertshttps://www.pharmaradar360.com/article/50f416c0d6fc2994PharmaRadar360en2026-04-21T06:10:00.000Zbio:cap 2026: Wo KI auf Life-Science triffthttps://www.pharmaradar360.com/article/0e2c0574e161c466PharmaRadar360en2026-04-21T06:02:35.000ZAvacta data at AACR 2026 underline favorable profile of AVA6103 and advantages of pre|CISION® delivery platformhttps://www.pharmaradar360.com/article/f4f463a408a85c8bPharmaRadar360en2026-04-21T06:00:00.000ZParlons Santé !, la lettre d’info qui prend soin de voushttps://www.pharmaradar360.com/article/87c7afe525052134PharmaRadar360en2026-04-21T05:33:16.000ZScientists discover skincare compound that kills drug-resistant bacteriahttps://www.pharmaradar360.com/article/dd974e71cc5328b2PharmaRadar360en2026-04-21T05:28:00.000ZFAIR4Rare abgeschlossenhttps://www.pharmaradar360.com/article/2d05e373d46ccd61PharmaRadar360en2026-04-21T05:01:35.000ZInvestors Sound Off on BCI Hype, Regulatory Risk, and the AI Gold Rushhttps://www.pharmaradar360.com/article/85471b7a10a7a1afPharmaRadar360en2026-04-21T05:00:00.000ZThis simple house may help prevent multiple fatal diseases in African childrenhttps://www.pharmaradar360.com/article/0fc22983a78f6de5PharmaRadar360en2026-04-21T05:00:00.000ZFDA accepts application for Roche’s Gazyva/Gazyvaro for the treatment of the most common form of lupushttps://www.pharmaradar360.com/article/9c03783f2913e5a1PharmaRadar360en2026-04-21T04:50:00.000ZWhistleblower alleges Finnish startup’s vaunted solid-state battery isn’t what it claimshttps://www.pharmaradar360.com/article/9b4be12eab087cf0PharmaRadar360en2026-04-21T04:00:00.000Z#RASSEGNASTAMPA. I trattamenti innovativi per gli occhi: Tommaso Nuzzo a TG4 Medicinahttps://www.pharmaradar360.com/article/af33e43f71631351PharmaRadar360en2026-04-21T03:47:00.000ZGilead loosens ties to Arcus after TIGIT dream finally ends in phase 3 failurehttps://www.pharmaradar360.com/article/de8f27079a21caf5PharmaRadar360en2026-04-21T03:37:13.000ZFDA’s Pep(tide) Rally! What Compounders and Industry Need to Know (Post 1 of 2)https://www.pharmaradar360.com/article/da8a4abfa1c8637bPharmaRadar360en2026-04-21T03:26:42.000ZTourists more likely to undergo unnecessary imaging in the EDhttps://www.pharmaradar360.com/article/b2cb948acfdb826aPharmaRadar360en2026-04-21T03:00:00.000Z[ANZEN]Revisions of PRECAUTIONS: Infliximab (genetical recombination) and biosimilars , etc. postedhttps://www.pharmaradar360.com/article/33934394b10ed173PharmaRadar360en2026-04-21T02:40:36.000ZCleanAssure Launched as an ISO Class 5 Controlled Cleanroom for Sterile Single-Use Assemblieshttps://www.pharmaradar360.com/article/dc78d9a418498b79PharmaRadar360en2026-04-21T02:36:52.000ZHospital system pours $20M into expanding imaging, oncology serviceshttps://www.pharmaradar360.com/article/8c2df7cf2dc7519ePharmaRadar360en2026-04-21T02:22:00.000ZHow to Choose a Financial Planner Without Regret: A Practical Guide for Pharmacistshttps://www.pharmaradar360.com/article/2e9865bff6959a87PharmaRadar360en2026-04-21T02:15:28.000Z1枚の眼底写真から体の年齢を示す「網膜年齢」を推定するAIを開発-糖尿病・心疾患・脳卒中との関連を確認-https://www.pharmaradar360.com/article/bd44e7a8ed39b1e0PharmaRadar360en2026-04-21T02:05:00.000ZWatch a spider’s heart race when traffic gets too loudhttps://www.pharmaradar360.com/article/a114240f130970d9PharmaRadar360en2026-04-21T01:57:28.000ZCRISPR Screens Map Human T‑Cell Genes That Promote or Block HIV Infectionhttps://www.pharmaradar360.com/article/01d636659d58a46cPharmaRadar360en2026-04-21T01:57:00.000ZNWA Heart Walk spotlights how heart disease can strike at any agehttps://www.pharmaradar360.com/article/2b83cc6e73c86451PharmaRadar360en2026-04-21T01:48:11.000ZArquitecto UC colabora con la NASA y trabaja en el diseño de las futuras bases en la lunahttps://www.pharmaradar360.com/article/d7b38cfa80be5f79PharmaRadar360en2026-04-21T01:31:59.000ZTEMPO 420 SChttps://www.pharmaradar360.com/article/c9acd1f44286fed9PharmaRadar360en2026-04-21T01:31:36.000ZTEMPO 420 SChttps://www.pharmaradar360.com/article/d240bd3023e0f7ecPharmaRadar360en2026-04-21T01:00:00.000ZEfficacy of Lactic Acid Bacterium ONRICb0240 Against Gingivitis ConfirmedA collaborative study with the Institute of Science Tokyo brings new hope for oral carehttps://www.pharmaradar360.com/article/1c2c8d1bb8df8737PharmaRadar360en2026-04-21T00:19:56.000ZPreclinical Evaluation of Allogeneic BCMA/CD70 Dual CAR T Cells for High-Risk Multiple Myelomahttps://www.pharmaradar360.com/article/5678e64a3b74273ePharmaRadar360en2026-04-21T00:00:00.000ZUpdate on the Phase 3 STAR-121 Study of Anti-TIGIT Antibody Domvanalimab and Anti-PD-1 Antibody Zimberelimab in Non-Small Cell Lung Cancerhttps://www.pharmaradar360.com/article/1073bc263e090ff2PharmaRadar360en2026-04-21T00:00:00.000ZTMEM87A suppresses ferroptosis and increases cancer immunotherapy resistance by maintaining the Golgi apparatus pH homeostasishttps://www.pharmaradar360.com/article/0b163ba77555e56fPharmaRadar360en2026-04-21T00:00:00.000ZNanoplate based digital PCR assay for effective quantification of plasma HPV circulating tumor DNAhttps://www.pharmaradar360.com/article/1f98949f9a9a281dPharmaRadar360en2026-04-21T00:00:00.000ZGenomic approaches for understanding the evolution of the human brainhttps://www.pharmaradar360.com/article/9d7ff018e805f381PharmaRadar360en2026-04-21T00:00:00.000ZConstituent-constrained word prediction during language comprehensionhttps://www.pharmaradar360.com/article/7aecaf0d00785a40PharmaRadar360en2026-04-21T00:00:00.000ZShow us the evidence for the value of medical AIhttps://www.pharmaradar360.com/article/6b9c077ea5eaa286PharmaRadar360en2026-04-21T00:00:00.000ZModifying exposure to plastic-associated chemicals in daily livinghttps://www.pharmaradar360.com/article/a55a3a762edcd299PharmaRadar360en2026-04-21T00:00:00.000ZExposure to negative physical and social factors accelerates brain aginghttps://www.pharmaradar360.com/article/a2553bc7ec5c03f9PharmaRadar360en2026-04-21T00:00:00.000ZThe Q-MONSTAR consortium: advancing fault-tolerant quantum computing for precision oncologyhttps://www.pharmaradar360.com/article/e91948ff50e9eaa3PharmaRadar360en2026-04-21T00:00:00.000ZThe patient is now in the roomhttps://www.pharmaradar360.com/article/b8e8d41492e88678PharmaRadar360en2026-04-21T00:00:00.000ZIs AI actually improving healthcare?https://www.pharmaradar360.com/article/d267e78f6155d2b3PharmaRadar360en2026-04-21T00:00:00.000ZDaily briefing: Should we worry about AI doomsday?https://www.pharmaradar360.com/article/1f6856db38342a11PharmaRadar360en2026-04-21T00:00:00.000ZUS speeds research into mind-altering drugs — including mysterious ‘ibogaine’